^
    Back
    Association details:
    Biomarker:PD-L1 overexpression + MET exon 14 mutation
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lung Cancer
    Title:

    Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration

    Published date:
    05/29/2021
    Excerpt:
    We report a patient who presented with stage IIIB lung adenocarcinoma with high PD-L1 expression (80%)...The patient quickly progressed and was found to harbor a MET exon 14 splice site alteration for which she received crizotinib and had a good response.
    DOI:
    10.1016/j.lungcan.2021.05.033